



PATENT
Attorney Docket No.: PP019813.0003

I hereby certify that this paper is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Karen Shure

12/10/2008
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Mariagrazia Pizza and Vega Massignani

Serial No.: 10/526,125

Confirmation No.: 2934

Filing Date: June 15, 2006

Group Art Unit: 1652

For: MUTANT FORMS OF MENINGOCOCCAL ADP-RIBOSYLATING TOXIN

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56 and in accordance with 37 C.F.R. §§ 1.97 and 1.98, information relating to the above-identified application is hereby disclosed, the Examiner in charge of the above-identified application is requested to consider and make of record the references listed on Form PTO/SB/08, submitted herewith.

Inclusion of the information submitted herewith is not to be construed as an admission that the information is material as that term is defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

This Information Disclosure Statement is being filed:

- within three months of the filing date of the patent application.
- within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 of the international application.

12/15/2008 CNGUYEN2 00000013 031664 10526125
01 FC:1806 180.00 DA

- before the mailing date of a first Office Action on the merits.
- after the mailing date of a first Office Action on the merits, but before the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, and accordingly is accompanied by:
 - the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below);
or
 - the Fee of \$180.00 set forth in 37 C.F.R. § 1.17(p); or
 - No fee is owed by the applicant(s).
- In accordance with 37 C.F.R. § 1.129(a), this Information Disclosure Statement is being filed in connection with the first or second After Final Submission, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below) and the fee of \$180.00 as set forth in 37 C.F.R. § 1.17(p), is attached.
- after the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, but before the payment of the Issue Fee, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e), (see "Statement," and "Fees" below).
- Copies of each of the non-U.S. Patent documents listed on the attached Form PTO/SB/08, are enclosed herewith.

EXCEPT THAT:

- In view of the voluminous nature of reference @@, and the likelihood that this reference is available to the Examiner, copies are not enclosed herewith.
- In accordance with 37 C.F.R. § 1.98(d), copies of the following references listed on the attached Form PTO/SB/08 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and

Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application.

If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

Concise Explanation Requirement

The "concise explanation" requirement (non-English references) for reference B2 under 37 C.F.R. § 1.98(a)(3) is satisfied by:

- the explanation provided on the attached sheet.
- the explanation provided in the Specification.
- submission of the enclosed International Search Report.
- submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action..
- the English-language abstract provided on the cover page of B2.

Statement under 37 C.F.R. § 1.97(e)

The undersigned attorney hereby states that each item contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.

Fees

No Fee is owed by the applicant(s).

The Information Disclosure Statement Fee of \$180.00 under 37 C.F.R. § 1.17(p) is enclosed herewith.

Method of Payment of Fees

- Attached is a check in the amount of \$_____ . This form is submitted in duplicate.
- Charge Deposit Account No. 03-1664 in the amount of \$180.00. This form is submitted in duplicate.
- Please charge any deficiency or credit any overpayment to Deposit Account 03-1664.
- No fee or Statement is required under 37 C.F.R. § 1.97(b).

Respectfully submitted,

Dated: Dec 9, 2008

By: 
Amy Hessler
Registration No. 50,310

NOVARTIS VACCINES AND DIAGNOSTICS, INC.
Intellectual Property Dept. – X100B
4560 Horton Street
Emeryville, CA 94608-2916
Telephone: (510) 923-2192
Facsimile: (510) 655-3542